Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
暂无分享,去创建一个
P. Porter | S. Riddell | Anusha Rajan | D. Sommermeyer | Paula L. Kosasih | L. Koch | B. Hoffstrom | C. Berger | Ashwini Balakrishnan | T. Goodpaster | J. Randolph-Habecker | F. Jalikis | Tracy Goodpaster
[1] Yu-Sun Chang,et al. Expression of ROR1 has prognostic significance in triple negative breast cancer , 2016, Virchows Archiv.
[2] Kole T. Roybal,et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.
[3] K. Yanagisawa,et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1 , 2016, Nature Communications.
[4] David Allman,et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.
[5] Wendell A. Lim,et al. Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.
[6] B. Kim,et al. Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma. , 2015, Annals of diagnostic pathology.
[7] M. Hochmair,et al. Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer , 2015, Oncoscience.
[8] J. Bading,et al. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.
[9] G. Widhopf,et al. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations , 2015, PloS one.
[10] G. Widhopf,et al. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. , 2015, Clinical lymphoma, myeloma & leukemia.
[11] Y. Li,et al. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma , 2015, PloS one.
[12] A. Österborg,et al. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies , 2015, British journal of haematology.
[13] Emanuela M. Ghia,et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy , 2014, Proceedings of the National Academy of Sciences.
[14] S. Riddell,et al. Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.
[15] Jin Zhu,et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer , 2014, Scientific Reports.
[16] F. de Marinis,et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. , 2014, Translational lung cancer research.
[17] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[18] S. Riddell,et al. Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma , 2013, PloS one.
[19] A. Österborg,et al. The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells , 2013, PloS one.
[20] S. Riddell,et al. Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.
[21] M. Jeddi-Tehrani,et al. Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells , 2013, PloS one.
[22] S. Sleijfer,et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] L. Rassenti,et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. , 2013, Cancer research.
[24] Michel Sadelain,et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.
[25] J. Khan,et al. Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies , 2012, PloS one.
[26] Wendy Frankel,et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. , 2012, The American journal of pathology.
[27] B. Druker,et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. , 2012, Cancer cell.
[28] W. Wilson,et al. Targeting malignant B cells with an immunotoxin against ROR1 , 2012, mAbs.
[29] N. Cheung,et al. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy , 2012, Front. Oncol..
[30] Tomoya Yamaguchi,et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. , 2012, Cancer cell.
[31] J. Wang-Rodriguez,et al. ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth , 2012, PloS one.
[32] M. Jeddi-Tehrani,et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells , 2012, Leukemia.
[33] A. Kozubík,et al. Post‐translational modifications regulate signalling by Ror1 , 2011, Acta physiologica.
[34] Thomas M. Schmitt,et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.
[35] C. Rooney,et al. Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.
[36] T. Sayers,et al. New flow cytometric assays for monitoring cell-mediated cytotoxicity , 2010, Expert review of vaccines.
[37] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] Jason S. Mitchell,et al. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. , 2009, Critical reviews in immunology.
[39] C. Larsson,et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy , 2008, International journal of cancer.
[40] E. Butcher,et al. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking , 2008, Nature Immunology.
[41] B. Engels,et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette , 2008, Journal of Molecular Medicine.
[42] L. Rassenti,et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a , 2008, Proceedings of the National Academy of Sciences.
[43] Adrian Wiestner,et al. Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia , 2008, Clinical Cancer Research.
[44] I. Pastan,et al. Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.
[45] Si-young Song,et al. Retinoic acid imprints gut-homing specificity on T cells. , 2004, Immunity.
[46] F. Marincola,et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.
[47] Y. Tu,et al. Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.
[48] David Botstein,et al. Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.
[49] S. Ashton,et al. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development , 2001, Development Genes and Evolution.
[50] D. Pleasure,et al. Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains. , 1996, Oncogene.